Patient characteristics
| Characteristics (n = 221) . | Median (IQR) or n (%) . |
|---|---|
| Age at diagnosis, y | 54 (50-59) |
| Sex | |
| Female | 83 (38) |
| Male | 138 (62) |
| Albumin | |
| ≥3.5 | 136 (61.5) |
| <3.5 | 51 (23) |
| Missing | 34 (15.5) |
| B2M | |
| <3.5 | 98 (44.3) |
| 3.5-5.5 | 49 (22.1) |
| >5.5 | 47 (21.2) |
| Missing | 27 (12.4) |
| LDH | |
| High | 36 (16.2) |
| Normal | 117 (52.9) |
| Missing | 68 (30.9) |
| Light/heavy chain | |
| IgGκ | 91 (41.2) |
| IgAκ | 27 (12.2) |
| IgGλ | 36 (16.3) |
| IgAλ | 16 (7.3) |
| LCκ | 36 (16.3) |
| LCλ | 10 (4.5) |
| Nonsecretory | 5 (2.2) |
| Presenting features | |
| Renal impairment | 20 (9) |
| Anemia | 66 (29.8) |
| Hypercalcemia | 11 (4.9) |
| Weight loss | 9 (2.8) |
| Incidental | 9 (2.8) |
| Fractures | 73 (33) |
| Bone lesions | 176 (79.6) |
| ISS at diagnosis | |
| I | 78 (35.2) |
| II | 67 (30.3) |
| III | 49 (22.1) |
| Missing | 27 (12.2) |
| R-ISS at diagnosis | |
| I | 23 (10.4) |
| II | 41 (18.5) |
| III | 16 (7.2) |
| Missing | 141 (63.8) |
| FISH | |
| Standard risk | 88 (39.8) |
| High risk | 12 (5.4) |
| Missing | 121 (54.8) |
| FISH (n = 100) | |
| del 13q14 | 16 (7.2) |
| del 17p | 8 (3.6) |
| t(11;14) | 5 (2.3) |
| t(4;14) | 4 (1.8) |
| Normal | 67 (30.3) |
| Lenalidomide exposure before transplant, n (%) | 5 (2.2) |
| First line | |
| VTD | 93 (42) |
| VCD | 40 (18) |
| TD | 29 (13) |
| CTD | 16 (7.2) |
| Others | 43 (19) |
| Pre-HSCT response | |
| sCR | 5 (2.2) |
| CR | 28 (12.6) |
| VGPR | 111 (50.2) |
| PR | 65 (29.4) |
| Age at HSCT, y | 54.7 (33-68) |
| Time from diagnosis to HSCT, mo | 10 (7-14) |
| Melphalan dose (mg/m2) | |
| 200 | 208 (94) |
| 140 | 13 (6) |
| Cell dose (×106 CD34+ cells per kg) | 4.62 (4.02-5.43) |
| Engraftment (median in days, range) | |
| Neutrophil | 11 (11-12) |
| Platelet | 16 (16-17) |
| Maintenance post-HSCT | 20 (9) |
| Lenalidomide | 15 (6.8) |
| Thalidomide | 5 (2.2) |
| Second HSCT | 43 (19.5) |
| Tandem | 22 (51) |
| Salvage | 21 (49) |
| Characteristics (n = 221) . | Median (IQR) or n (%) . |
|---|---|
| Age at diagnosis, y | 54 (50-59) |
| Sex | |
| Female | 83 (38) |
| Male | 138 (62) |
| Albumin | |
| ≥3.5 | 136 (61.5) |
| <3.5 | 51 (23) |
| Missing | 34 (15.5) |
| B2M | |
| <3.5 | 98 (44.3) |
| 3.5-5.5 | 49 (22.1) |
| >5.5 | 47 (21.2) |
| Missing | 27 (12.4) |
| LDH | |
| High | 36 (16.2) |
| Normal | 117 (52.9) |
| Missing | 68 (30.9) |
| Light/heavy chain | |
| IgGκ | 91 (41.2) |
| IgAκ | 27 (12.2) |
| IgGλ | 36 (16.3) |
| IgAλ | 16 (7.3) |
| LCκ | 36 (16.3) |
| LCλ | 10 (4.5) |
| Nonsecretory | 5 (2.2) |
| Presenting features | |
| Renal impairment | 20 (9) |
| Anemia | 66 (29.8) |
| Hypercalcemia | 11 (4.9) |
| Weight loss | 9 (2.8) |
| Incidental | 9 (2.8) |
| Fractures | 73 (33) |
| Bone lesions | 176 (79.6) |
| ISS at diagnosis | |
| I | 78 (35.2) |
| II | 67 (30.3) |
| III | 49 (22.1) |
| Missing | 27 (12.2) |
| R-ISS at diagnosis | |
| I | 23 (10.4) |
| II | 41 (18.5) |
| III | 16 (7.2) |
| Missing | 141 (63.8) |
| FISH | |
| Standard risk | 88 (39.8) |
| High risk | 12 (5.4) |
| Missing | 121 (54.8) |
| FISH (n = 100) | |
| del 13q14 | 16 (7.2) |
| del 17p | 8 (3.6) |
| t(11;14) | 5 (2.3) |
| t(4;14) | 4 (1.8) |
| Normal | 67 (30.3) |
| Lenalidomide exposure before transplant, n (%) | 5 (2.2) |
| First line | |
| VTD | 93 (42) |
| VCD | 40 (18) |
| TD | 29 (13) |
| CTD | 16 (7.2) |
| Others | 43 (19) |
| Pre-HSCT response | |
| sCR | 5 (2.2) |
| CR | 28 (12.6) |
| VGPR | 111 (50.2) |
| PR | 65 (29.4) |
| Age at HSCT, y | 54.7 (33-68) |
| Time from diagnosis to HSCT, mo | 10 (7-14) |
| Melphalan dose (mg/m2) | |
| 200 | 208 (94) |
| 140 | 13 (6) |
| Cell dose (×106 CD34+ cells per kg) | 4.62 (4.02-5.43) |
| Engraftment (median in days, range) | |
| Neutrophil | 11 (11-12) |
| Platelet | 16 (16-17) |
| Maintenance post-HSCT | 20 (9) |
| Lenalidomide | 15 (6.8) |
| Thalidomide | 5 (2.2) |
| Second HSCT | 43 (19.5) |
| Tandem | 22 (51) |
| Salvage | 21 (49) |
CTD, cyclophosphamide, thalidomide, and dexamethasone; B2M, β-2 microglobulin; LC, light chain; LDH, lactate dehydrogenase; TD, thalidomide and dexamethasone.